胸腺肽α1预防乙型肝炎病毒再激活临床研究

The clinical research of Thymosin-α1 in preventing Hepatitis B Virus (HBV) to reactivate

目的观察胸腺肽α1(Tα1)在预防肺结核合并乙型肝炎患者抗结核治疗后乙型肝炎病毒(HBV)再激活中的作用。方法将72例肺结核合并乙型肝炎病毒感染患者按入院先后分为治疗组(36例)和对照组(36例)。治疗组除给予常规抗结核治疗外,给予胸腺肽α11.6mg皮下注射,每周2次。对照组仅给予常规抗结核治疗。抗结核治疗后1、2、3个月检测肝功能及HBV-DNA,观察两组患者HBV再激活发生例数。结果治疗组36例患者中发生HBV再激活者12例,发生率为33.33%(12/36)。对照组36例患者中发生HBV再激活者20例,发生率为55.56%(20/36)。经统计学处理,P<0.05。结论肺结核合并乙型肝炎患者,在抗结核治疗期间,给予胸腺肽α1治疗,可以起到预防发生乙型肝炎病毒再激活的作用。

Objective To observe the action of thymosin-α1 in preventing the reactivation of HBV in the patients who suffered from pulmonary tuberculosis with HBV infection after accepting antitubercular treatment.Methods Seventy two pulmonary tuberculosis inpatients with HBV infection were divided into the treatment group (36 cases) and control group (36 cases) according to the order of being in hospital.In addition to conventional antitubercular treatment,the treatment group were given thymosin-α1 1.6 mg through subcutaneous injection,2 times a week.The control group limited to conventional antitubercular treatment.1 month,2 months and 3 months after treatment,every case tested liver function and HBV-DNA quantitative to observe the reactivate HBV happened number in each group.Results Twelve cases in the treatment group and 20 cases in the control group were observed the reactivation of HBV.There was significant difference between the two groups in the rate of the reactivation of HBV (P < 0.05).Conclusion Thymosin-α1 treatment can prevent HBV to reactivate in the pulmonary tuberculosis patients with HBV infection in the period of antitubercular treatment preventing HBV to reactivate.